256 related articles for article (PubMed ID: 34359636)
1. Targeting
Linn P; Kohno S; Sheng J; Kulathunga N; Yu H; Zhang Z; Voon D; Watanabe Y; Takahashi C
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359636
[TBL] [Abstract][Full Text] [Related]
2. Targeted Inhibition of the E3 Ligase SCF
Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
[TBL] [Abstract][Full Text] [Related]
3. Understanding Retinoblastoma Post-Translational Regulation for the Design of Targeted Cancer Therapies.
Janostiak R; Torres-Sanchez A; Posas F; de Nadal E
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267571
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Strategies for RB1-Deficient Cancers: Intersecting Gene Regulation and Targeted Therapy.
Huang MF; Wang YX; Chou YT; Lee DF
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672640
[TBL] [Abstract][Full Text] [Related]
5. Deletions of Retinoblastoma 1 (Rb1) and Its Repressing Target S Phase Kinase-associated protein 2 (Skp2) Are Synthetic Lethal in Mouse Embryogenesis.
Zhao H; Wang H; Bauzon F; Lu Z; Fu H; Cui J; Zhu L
J Biol Chem; 2016 May; 291(19):10201-9. PubMed ID: 26966181
[TBL] [Abstract][Full Text] [Related]
6. Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the
Gong X; Du J; Parsons SH; Merzoug FF; Webster Y; Iversen PW; Chio LC; Van Horn RD; Lin X; Blosser W; Han B; Jin S; Yao S; Bian H; Ficklin C; Fan L; Kapoor A; Antonysamy S; Mc Nulty AM; Froning K; Manglicmot D; Pustilnik A; Weichert K; Wasserman SR; Dowless M; Marugán C; Baquero C; Lallena MJ; Eastman SW; Hui YH; Dieter MZ; Doman T; Chu S; Qian HR; Ye XS; Barda DA; Plowman GD; Reinhard C; Campbell RM; Henry JR; Buchanan SG
Cancer Discov; 2019 Feb; 9(2):248-263. PubMed ID: 30373917
[TBL] [Abstract][Full Text] [Related]
7. Interchangeable Roles for E2F Transcriptional Repression by the Retinoblastoma Protein and p27KIP1-Cyclin-Dependent Kinase Regulation in Cell Cycle Control and Tumor Suppression.
Thwaites MJ; Cecchini MJ; Passos DT; Welch I; Dick FA
Mol Cell Biol; 2017 Jan; 37(2):. PubMed ID: 27821477
[TBL] [Abstract][Full Text] [Related]
8. Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.
Knudsen ES; Pruitt SC; Hershberger PA; Witkiewicz AK; Goodrich DW
Trends Cancer; 2019 May; 5(5):308-324. PubMed ID: 31174843
[TBL] [Abstract][Full Text] [Related]
9. Genomic instability and proliferation/survival pathways in RB1-deficient malignancies.
Pappas L; Xu XL; Abramson DH; Jhanwar SC
Adv Biol Regul; 2017 May; 64():20-32. PubMed ID: 28242412
[TBL] [Abstract][Full Text] [Related]
10. Collateral Lethality: A new therapeutic strategy in oncology.
Muller FL; Aquilanti EA; DePinho RA
Trends Cancer; 2015 Nov; 1(3):161-173. PubMed ID: 26870836
[TBL] [Abstract][Full Text] [Related]
11. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
[TBL] [Abstract][Full Text] [Related]
12. p16 controls epithelial cell growth and suppresses carcinogenesis through mechanisms that do not require RB1 function.
Sen M; Akeno N; Reece A; Miller AL; Simpson DS; Wikenheiser-Brokamp KA
Oncogenesis; 2017 Apr; 6(4):e320. PubMed ID: 28414317
[TBL] [Abstract][Full Text] [Related]
13. Human pituitary adenomas infrequently contain inactivation of retinoblastoma 1 gene and activation of cyclin dependent kinase 4 gene.
Honda S; Tanaka-Kosugi C; Yamada S; Sano T; Matsumoto T; Itakura M; Yoshimoto K
Endocr J; 2003 Jun; 50(3):309-18. PubMed ID: 12940460
[TBL] [Abstract][Full Text] [Related]
14. Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines.
Huang L; Lang D; Geradts J; Obara T; Klein-Szanto AJ; Lynch HT; Ruggeri BA
Mol Carcinog; 1996 Feb; 15(2):85-95. PubMed ID: 8599583
[TBL] [Abstract][Full Text] [Related]
15. Linc00441 interacts with DNMT1 to regulate RB1 gene methylation and expression in gastric cancer.
Zhou J; Shi J; Fu X; Mao B; Wang W; Li W; Li G; Zhou S
Oncotarget; 2018 Dec; 9(101):37471-37479. PubMed ID: 30680063
[TBL] [Abstract][Full Text] [Related]
16. RB1 in cancer: different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis.
Di Fiore R; D'Anneo A; Tesoriere G; Vento R
J Cell Physiol; 2013 Aug; 228(8):1676-87. PubMed ID: 23359405
[TBL] [Abstract][Full Text] [Related]
17. Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma.
Dimaras H; Khetan V; Halliday W; Orlic M; Prigoda NL; Piovesan B; Marrano P; Corson TW; Eagle RC; Squire JA; Gallie BL
Hum Mol Genet; 2008 May; 17(10):1363-72. PubMed ID: 18211953
[TBL] [Abstract][Full Text] [Related]
18. RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy.
Indovina P; Pentimalli F; Casini N; Vocca I; Giordano A
Oncotarget; 2015 Jul; 6(20):17873-90. PubMed ID: 26160835
[TBL] [Abstract][Full Text] [Related]
19. Targeting the RB-E2F pathway in breast cancer.
Johnson J; Thijssen B; McDermott U; Garnett M; Wessels LF; Bernards R
Oncogene; 2016 Sep; 35(37):4829-35. PubMed ID: 26923330
[TBL] [Abstract][Full Text] [Related]
20. Failure of RB1 to reverse the malignant phenotype of human tumor cell lines.
Muncaster MM; Cohen BL; Phillips RA; Gallie BL
Cancer Res; 1992 Feb; 52(3):654-61. PubMed ID: 1732054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
